- LatestICM and FIGO launch joint statement on the use of misoprostol for the treatment of postpartum haemorrhage.
- LatestMarigat officials 'taking bribes to allow FGM'
- LatestUK government praises newspaper for raising awareness of FGM
- LatestHIV/Aids cases on the up in Indonesian district
- LatestFIGO supports International Women’s Day 2014 (8 March): ‘Inspiring Change’
- LatestNew FIGO resources on www.glowm.com: Family Planning and Prevention of Unsafe Abortion
Misoprostol for postpartum hemorrhage: Moving from evidence to practice
Publication year: 2011
Source: International Journal of Gynecology & Obstetrics, Available online 10 November 2011
Ann Starrs, Beverly Winikoff
Clinical and operational evidence indicates that misoprostol is a safe and effective technology for addressing postpartum hemorrhage, a major cause of maternal death. This research has not yet been translated into effective policies, programs, and practice in many parts of the world. Efforts to expand evidence-based use of misoprostol are often complicated by misoprostol's range of indications, insufficient availability, a lack of evidence-based guidelines and provider training, and misconceptions about the drug. The medical and health policy communities need to work together to translate research findings into changes in policy, knowledge, and clinical practice so that we can deliver on the world's promise to improve maternal health.